Rajeev Saggar Sells 50,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the completion of the transaction, the insider directly owned 142,265 shares of the company’s stock, valued at approximately $10,536,145.90. This represents a 26.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Rajeev Saggar also recently made the following trade(s):

• On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The shares were sold at an average price of $76.84, for a total transaction of $2,269,392.56.
• On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total transaction of $709,808.26.

Liquidia Price Performance

NASDAQ LQDA opened at $71.05 on Friday. The company has a market cap of $6.36 billion, a price-to-earnings ratio of 51.86 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The stock’s fifty day moving average price is $79.34 and its 200 day moving average price is $56.13. Liquidia Corporation has a 1 year low of $21.15 and a 1 year high of $93.61.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The business’s revenue was up 1842.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.49) EPS. As a group, equities research analysts forecast that Liquidia Corporation will post 2.57 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently modified their holdings of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after acquiring an additional 1,700 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares during the period. Creative Planning lifted its holdings in Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after acquiring an additional 7,765 shares during the period. Finally, Legal & General Group Plc boosted its position in Liquidia by 13.4% in the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on LQDA shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $106.00 target price on shares of Liquidia in a report on Thursday, August 13th. Bank of America increased their price target on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Piper Sandler set a $129.00 price target on shares of Liquidia in a research report on Friday, July 24th. Royal Bank Of Canada set a $130.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Finally, Needham & Company LLC upped their price objective on shares of Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $98.08.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).